NLS Pharmaceuticals Ltd. (NASDAQ: NLSP) Releases Data Showing Mazindol’s Agonist Activity in Narcolepsy Treatment

July 9, 2021

NLS Pharmaceuticals Ltd. (NASDAQ: NLSP) has released new study data supporting mazindol’s action mechanism. Mazindol is an active compound in NLS Pharmaceutical’s flagship product candidate for narcolepsy, Quilience, treatment.  Mazindol shows OX2R agonist activity  The released data confirmed the agonist activity of mazindol’s Orexin receptor (OX2R). In NLS sponsored pre-clinical study carried by the University of Lausanne’s Biomedical Sciences Department, genetically modified mice not to show OX2R and Wild-Type mice…